TARSTarsus Pharmaceuticals, Inc.

Nasdaq tarsusrx.com


$ 36.89 $ 2.22 (6.41 %)    

Friday, 03-May-2024 15:59:36 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 36.85
$ 36.11
$ 0.00 x 0
$ 0.00 x 0
$ 35.60 - $ 37.03
$ 12.57 - $ 40.40
684,003
na
1.08B
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-27-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-17-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-14-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 11-25-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tarsus-prices-100m-public-offering-of-2812500-common-shares-at-32share

Tarsus Pharmaceuticals announced the pricing of an underwritten public offering of 2,812,500 shares of its common stock at a pu...

 tarsus-pharmaceuticals-reveals-proposed-100m-public-offering

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its co...

 goldman-sachs-maintains-neutral-on-tarsus-pharmaceuticals-raises-price-target-to-30

Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target f...

 hc-wainwright--co-maintains-buy-on-tarsus-pharmaceuticals-raises-price-target-to-57

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price t...

 barclays-maintains-overweight-on-tarsus-pharmaceuticals-raises-price-target-to-50

Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target ...

 icu-medical-to-rally-around-28-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 oppenheimer-reiterates-outperform-on-tarsus-pharmaceuticals-raises-price-target-to-59

Oppenheimer analyst Francois Brisebois reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the pric...

 tarsus-pharmaceuticals-q4-eps-131-beats-136-estimate-sales-1308m-beat-566m-estimate

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate o...

 earnings-scheduled-for-february-27-2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

 sofi-technologies-posts-q4-earnings-joins-cardlytics-mcgrath-rentcorp-and-other-big-stocks-moving-higher-on-monday

U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOF...

 goldman-sachs-initiates-coverage-on-tarsus-pharmaceuticals-with-neutral-rating-announces-price-target-of-19

Goldman Sachs analyst Andrea Tan initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral rating and announ...

 why-wynn-resorts-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.

 big-stocks-moving-higher-on-friday-synaptics-reports-q1-beat-joins-lyft-hologic-blink-charging

U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: S...

 hc-wainwright--co-maintains-buy-on-tarsus-pharmaceuticals-raises-price-target-to-50

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION